Skip Navigation
Wilmer Eye Institute
Print This Page
Share this page: More

Current Research in Retina

The faculty in the Retina Division are currently working on the following research projects:

Susan Bressler, M.D.

All active protocols for the (Diabetes Clinical Research Network) including:

  • Comparison of ranibizumab + prompt or deferred laser vs triamcinolone + prompt laser vs focal/drid laser in the management of diabetic macular edema
  • Assessment of the reproducibility of multiple different spectral domain OCT instruments and comparison to time domain OCT among individuals with diabetes
  • Comparison of ranibizumab/bevacizumab/aflibercept in the management of diabetic macular edema
  • Evaluation of observation vs laser vs anti-VEGF therapy for eyes with diabetic macular edema and good vision

Assessment of home- monitoring of patients with age-related macular degeneration who are at high risk of progression to neovascular AMD.

Peter Campochiaro, M.D.

Retinal Cell & Molecular Laboratory

Daniel Finkelstein, M.D.

The Ethics of the Doctor-Patient Relationship: Using questionnaires and video recording to understand ways to encourage that relationship in order to foster “healing” and compliance.

Morton Goldberg, M.D.

Incontinentia  pigmenti: Dr. Goldberg is re-evaluating patients he initially studied up to two decades ago in order to determine the natural course and  proper treatment of this often severe disease, which is inherited only in females and can cause severe retinal (and cerebral) shutdown and overgrowth of arteries and veins, including major hemorrhages in the eye and brain.

Akrit Sodhi, M..D., Ph.D.

The role of HIF (hypoxic-inducible factor) regulation and dysregulation in ocular disease, with the goal of identifying novel therapeutic approaches for treatment of a variety of vision-threatening diseases:

  • Identification of a novel “bad” HIF target gene that promotes macular edema
  • Examination of the role of “good” HIF target genes in protecting the retina in dry AMD
  • Using HIF target genes to target and destroy pathological blood vessels in ocular neovascular disease.


Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer